S100A12 and Huntington disease: Gene set enrichment analysis revealed that AGE-HS treatment induced downregulation of gene sets linked to MYC, interferon responses, and oxidative phosphorylation, as well as pathways related to neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease, paralleling some effects observed with S100A12.